Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
International Rare Histiocytic Disorders Registry (IRHDR)
NCT02285582 · View on ClinicalTrials.gov ↗
Study Summary
The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that can be sometimes life-threatening. Since they are extremely rare, there is limited understanding of their causes and best treatment options. Physicians, patients and parents of children with RHDs frequently consult members of the Histiocyte Society regarding the best management of these disorders. Very often, no specific recommendation can be made due to the lack of prospective outcome data, or even large retrospective case series. The creation of an international rare histiocytic disorders registry (IRHDR) could facilitate a uniform diagnosis of the RHDs, as well as the collection and analysis of the clinical, epidemiological, treatment and survival data of patients with RHD. The registry may also lead to future therapeutic recommendations, provide a framework for future clinical trials and create excellent research opportunities.
Conditions Studied
Interventions
- OTHER Registry study
Study Locations (15)
Other
- Hospital Nacional de Pediatria Garrahan — Buenos Aires
- University Hospital Brno — Brno
- Rostock University Medical Hospital — Rostock
- Azienda Ospedaliero-Universitaria Meyer — Florence
- Children's Memorial Health Institute — Warsaw
- Hospital Universitario Cruces — Barakaldo
California
- Children's Hospital of Los Angeles — Los Angeles
- Valley Children's Hospital — Madera
Alabama
- The University of Alabama at Birmingham — Birmingham
Massachusetts
- Dana-Farber Cancer Institute — Boston
New York
- Memorial Sloan Kettering Cancer Center — New York
Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh
Ontario
- The Hospital for Sick Children — Toronto
Quebec
- Centre hospitalier universitaire Sainte-Justine — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2014-10 |
| Est. Completion | 2028-09 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02285582
The ClinicalTrials.gov registry entry for NCT02285582 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Hospital for Sick Children, which has 15 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Erdheim-Chester Disease (ECD) appearing as the primary indexed condition, and to 1 intervention — of which Registry study is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02285582 reports 15 study locations spanning 9 distinct geographic areas — top geographies include Other, California, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02285582 about?
NCT02285582 is a clinical study titled "International Rare Histiocytic Disorders Registry (IRHDR)". The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that can be sometimes life-threatening. Since they are extremely rare, there ...
What is the current status of trial NCT02285582?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2014-10. Estimated completion is 2028-09.
What conditions does trial NCT02285582 study?
This clinical trial studies the following conditions: Erdheim-Chester Disease (ECD), Rosai-Dorfman Disease (RDD), Rare Histiocytic Disorders (RHDs), Xanthogranuloma Family (XG), Indeterminate Dendritic Cell Histiocytosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02285582?
The interventions under investigation include: Registry study (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02285582?
This trial is sponsored by The Hospital for Sick Children, which has 15 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02285582 being conducted?
This trial has 15 study locations across Alabama, California, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.